Neratinib in Combination With Ruxolitinib in Patients With mTNBC
NCT ID: NCT06008275
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
EARLY_PHASE1
20 participants
INTERVENTIONAL
2024-09-16
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There is long standing evidence that EGFR is an important signaling pathway in metTNBC as this cancer overexpresses EGFR compared to other breast cancer subtypes. This exposes a pathway that is targetable for treatment, making EGFR a compelling molecular therapeutic target in metTNBC. Another key contributor to progression of TNBC is the JAK/STAT3 signaling pathway and assessments of EGFR have shown that it is a positive regulator of STAT3 that drives proliferation and survival of metTNBC.
The investigators hypothesize that combined inhibition of EGFR and JAK/STAT3 using neratinib and ruxolitinib will lead to greater inhibition of the critically important EGFR pathway in TNBC with greater efficacy than targeting EGFR or JAK/STAT3 alone.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
neratinib + ruxolitinib
There is only one arm
Neratinib Oral Tablet
240mg oral daily. Dosing will follow standard dose escalation procedures
Ruxolitinib Oral Tablet
20mg oral twice daily. Dosing will follow standard initial dose recommendation procedure
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neratinib Oral Tablet
240mg oral daily. Dosing will follow standard dose escalation procedures
Ruxolitinib Oral Tablet
20mg oral twice daily. Dosing will follow standard initial dose recommendation procedure
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Female patients ≥18 years of age
2. Have a diagnosis of metastatic TNBC previously treated with standard anthracycline, cyclophosphamide, and taxane chemotherapy, unless there was a contraindication to doxorubicin, in which case prior treatment with this agent is not required.
Note. TNBC defined as ER-negative tumors with ≤10% tumor nuclei immunoreactivity, or "ER Low Positive" as defined by the updated ASCO/CAP guidelines 2020.
3. Have not received more than 4 prior chemotherapy regimens for metastatic disease. Prior platinum and/or taxane therapy in the adjuvant or metastatic setting is permitted. Patients with more than 4 prior regimens may be allowed on study per physician discretion, if ECOG PS is 0-1.
4. Have locoregional (e.g., breast, chest wall, regional lymphatic) or pulmonary or hepatic metastatic disease that is amenable to core needle biopsy. If a research biopsy from a patient's metastatic disease cannot be safely obtained, a skin biopsy is permitted. If a skin biopsy cannot be safely obtained, patients may still be eligible, per physician discretion.
5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
6. Have adequate hematologic function, defined by:
1. Absolute neutrophil count (ANC) \>1500/µL
2. Platelet count ≥100,000/ µL
3. Hemoglobin ≥9 g/dL or ≥5.6 mmol/L
7. Have adequate liver function, defined by:
1. AST and ALT ≤2.5 x the upper limit of normal (ULN) or ≤5 x ULN in presence of liver metastases
2. Total bilirubin ≤1.5 x ULN OR direct bilirubin ≤ULN for patients with total bilirubin levels \>1.5 × ULN
8. Have adequate renal function, defined by:
a. Serum creatinine ≤1.5 x ULN or calculated creatinine clearance of ≥30 mL/min
9. Patients who have a history of brain metastasis are eligible for the study provided that all the following criteria are met:
10. Brain metastases which have been treated
11. Off-treatment with steroids before administration of the first dose of treatment
12. No ongoing requirement for dexamethasone or anti-epileptic drugs
13. No clinical or radiological evidence of progression of brain metastases
14. Patients must be accessible for treatment and follow-up.
15. All patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry.
Exclusion Criteria
1. Has received a live vaccine or live-attenuated vaccine within 30 days of the first dose of study treatment. Administration of killed vaccines is allowed.
2. Has peripheral neuropathy ≥grade 2
3. Has completed previous radiotherapy for metastatic disease \<2 weeks prior to study treatment initiation
4. Has an active infection requiring systemic therapy
5. Has significant cardiovascular disease, such as:
1. History of myocardial infarction, acute coronary syndrome, or coronary angioplasty/stenting/bypass grafting within the last 6 months
2. Congestive heart failure (CHF) New York Heart Association (NYHA) Class II-IV, or history of CHF NYHA class III or IV.
6. Has a known history of active tuberculosis
7. Women who are pregnant or lactating. All patients with reproductive potential must agree to use effective contraception from time of study entry until at least 3 months after the last administration of study drug.
8. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation such as:
1. severe impaired lung functions as defined as spirometry and DLCO that is 50% of the normal predicted value and/or O2 saturation that is 88% or less at rest on room air
2. liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class C).
9. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's full participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the Treating Physician.
10. Has received prior systemic anti-cancer therapy within 2 weeks prior to study treatment.
11. Has received investigational agents within 4 weeks prior to study treatment. Monoclonal antibody agents should have a 4-week (28 day) washout period.
12. Any other investigational or anti-cancer treatments while participating in this study
13. Any other active malignancy
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Baylor Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joyce A O'Shaughnessy, MD
Role: PRINCIPAL_INVESTIGATOR
Baylor Scott and White Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Baylor University Medical Center, Baylor Charles A Sammons Cancer Center
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Page E Blas, MA
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
023-340
Identifier Type: -
Identifier Source: org_study_id